Aktieanalys

BioArctic: Outlicenses PyroGlutamate-amyloid-beta antibody program to BMS - Redeye

{newsItem.title}

Redeye Publicerad: 19 Dec 09:13

Redeye endorses the news that BioArctic has signed a licensing agreement with BMS regarding BioArctic's PyroGlutamate-amyloid-beta antibody program and give our initial take.

Länk till analysen i sin helhet: https://www.redeye.se/research/1065697/bioarctic-outlicenses-pyroglutamate-amyloid-beta-antibody-program-to-bms?utm_source=finwire&utm_medium=RSS

Nyheter om BioArctic

Läses av andra just nu

Om aktien BioArctic

Senaste nytt